UPDATE: Epizyme Will Be Eligible To Receive Upfront Payment Of $15M Plus Added $5M in Research Funding In 2019; Is Eligible To Receive $280M+ In Added Payments For R&D, Regulatory, Commercial Milestones
Benzinga Newsdesk